Scarica l'app Stockscreener
11.88
0.29%
-0.05
Precedente Chiudi:
$11.93
Aprire:
$12
Volume 24 ore:
438.66K
Relative Volume:
0.24
Capitalizzazione di mercato:
$3.79B
Reddito:
$3.05B
Utile/perdita netta:
$181.32M
Rapporto P/E:
31.79
EPS:
0.3737
Flusso di cassa netto:
$225.64M
1 W Prestazione:
-6.92%
1M Prestazione:
-14.49%
6M Prestazione:
+2.81%
1 anno Prestazione:
+56.51%
Intervallo 1D:
$11.87
$12.23
Intervallo di 1 settimana:
$11.87
$12.82
Portata 52W:
$7.02
$15.42
Amneal Pharmaceuticals Inc Stock (AMRX) Company Profile
Nome
Amneal Pharmaceuticals Inc
Settore
Telefono
908-947-3120
Indirizzo
400 Crossing Boulevard, 3rd Floor, Bridgewater
Compare AMRX vs TAK, HLN, TEVA, ZTS, UTHR
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AMRX
Amneal Pharmaceuticals Inc
|
11.88 | 3.81B | 3.05B | 181.32M | 225.64M | 0.3737 |
TAK
Takeda Pharmaceutical Co Adr
|
16.52 | 52.48B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.135 | 39.72B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
33.94 | 39.93B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
77.62 | 31.12B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
566.89 | 24.13B | 3.17B | 1.29B | 1.01B | 27.09 |
Amneal Pharmaceuticals Inc Stock (AMRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-17 | Iniziato | UBS | Buy |
| 2025-12-09 | Iniziato | Barclays | Overweight |
| 2025-06-06 | Iniziato | Goldman | Buy |
| 2025-02-24 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2024-09-06 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2021-04-07 | Ripresa | RBC Capital Mkts | Sector Perform |
| 2021-03-08 | Aggiornamento | Goldman | Sell → Buy |
| 2020-12-14 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2020-12-14 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-07-27 | Iniziato | Goldman | Sell |
| 2020-05-12 | Aggiornamento | Guggenheim | Sell → Neutral |
| 2019-12-12 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2019-11-12 | Downgrade | JP Morgan | Neutral → Underweight |
| 2019-11-07 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2019-07-22 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2019-07-11 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-07-08 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2019-06-11 | Iniziato | Barclays | Equal Weight |
| 2019-05-21 | Aggiornamento | Raymond James | Mkt Perform → Strong Buy |
| 2019-03-20 | Iniziato | SunTrust | Buy |
| 2019-03-08 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2018-12-14 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2018-10-16 | Downgrade | SunTrust | Buy → Hold |
| 2018-08-13 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-07-23 | Iniziato | Morgan Stanley | Overweight |
| 2018-06-22 | Iniziato | B. Riley FBR, Inc. | Buy |
Mostra tutto
Amneal Pharmaceuticals Inc Borsa (AMRX) Ultime notizie
AMRX Should I Buy - Intellectia AI
3 Reasons Why Growth Investors Shouldn't Overlook Amneal (AMRX) - Yahoo! Finance Canada
Should Value Investors Buy Amneal Pharmaceuticals (AMRX) Stock? - Yahoo Finance
Here's why Amneal Pharmaceuticals (AMRX) is a strong growth stock - MSN
Amneal Pharmaceuticals' (NASDAQ:AMRX) Solid Earnings Are Supported By Other Strong Factors - Yahoo Finance
AMRX growth drivers: Generics, biosimilars, and Crexont - MSN
Assessing Amneal Pharmaceuticals (AMRX) Valuation After Recent Share Price Weakness - Sahm
Amneal (AMRX) director Deborah Autor sells 34,819 shares at $12.94 avg - Stock Titan
[144] Amneal Pharmaceuticals, Inc. SEC Filing - Stock Titan
Do options traders know something about Amneal stock we don't? - MSN
Amneal (AMRX) Q3 2025 Earnings Call Transcript - AOL.com
AMRX SEC FilingsAmneal Pharmaceuticals Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Amneal to buy Kashiv in $750M deal; raises FY26 EPS outlook - MSN
Amneal Pharmaceuticals (AMRX) Profit Rebound Challenges Concerns Over Earnings Quality - Sahm
[Form 4] Amneal Pharmaceuticals, Inc. Insider Trading Activity - Stock Titan
Amneal Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director BUCHI J KEVIN - Moomoo
Amneal (NYSE: AMRX) director exercises 34,819 RSUs and receives new grant - Stock Titan
Amneal (NYSE: AMRX) director settles RSUs, now holds 128,479 shares - Stock Titan
Amneal Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director George Jeffrey P. - Moomoo
Amneal (AMRX) director Jeffrey George exercises 34,819 RSUs, receives 19,824 new units - Stock Titan
Amneal (AMRX) director exercises RSUs, now holds 260,252 shares - Stock Titan
Director boosts stake with 34,819 shares in Amneal (NYSE: AMRX) - Stock Titan
Amneal (NYSE: AMRX) director exercises 48,747 RSUs and receives 30,837-unit grant - Stock Titan
Amneal (NYSE: AMRX) director converts RSUs to shares and gets new grant - Stock Titan
Amneal (AMRX) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates (Revised) - Yahoo Finance
Amneal Shareholders Back Board, Pay and Auditor at Meeting - TipRanks
Amneal Pharmaceuticals Q1 2026 & M&A announcement Earnings Call Transcript - MarketBeat
Amneal Pharmaceuticals (NASDAQ: AMRX) posts Q1 profit surge and inks $375M Kashiv acquisition - Stock Titan
Drugmaker Amneal posts $62M profit as specialty-drug sales rise 23% - Stock Titan
Amneal (NASDAQ: AMRX) investors back directors, say-on-pay and EY as auditor - Stock Titan
Earnings Flash (AMRX) Amneal Pharmaceuticals, Inc. Posts Q1 Adjusted EPS $0.27 per Share, vs. FactSet Est of $0.17 - marketscreener.com
Earnings Flash (AMRX) Amneal Pharmaceuticals, Inc. Reports Q1 Revenue $722.5M, vs. FactSet Est of $719.7M - marketscreener.com
Amneal (NASDAQ: AMRX) Q1 2026 profit soars as margins rise and guidance held - Stock Titan
Amneal Reports First Quarter 2026 Financial Results - The Manila Times
Earnings Flash (AMRX) Amneal Pharmaceuticals, Inc. Reports Q1 Revenue $722.5M, Vs. FactSet Est of $719.7M - Moomoo
Earnings Flash (AMRX) Amneal Pharmaceuticals, Inc. Posts Q1 Adjusted EPS $0.27 per Share, Vs. FactSet Est of $0.22 - Moomoo
Number of shareholders of Amneal Pharmaceuticals, Inc. – NASDAQ:AMRX - TradingView
Amneal Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Vishrut Awasthi Joins Amneal Pharmaceuticals to Lead India Strategy and Business Development - hrtoday.in
Amneal Pharmaceuticals Kashiv Deal Puts Biosimilar Growth And Valuation In Focus - Yahoo Finance
Do Options Traders Know Something About Amneal Stock We Don't? - Yahoo Finance
How The Amneal Pharmaceuticals (AMRX) Story Is Shifting Around The New US$17 Price Target - Yahoo Finance
Earnings call transcript: Amneal Pharma Q1 2026 Surpasses EPS Forecast By Investing.com - Investing.com Nigeria
Earnings call transcript: Amneal Pharma Q1 2026 Surpasses EPS Forecast - Investing.com
Amneal Pharmaceuticals Q1 2026 earnings preview - MSN
How CREXONT’s Positive Phase 4 Data and Reaffirmed Outlook Could Shape Amneal Pharmaceuticals (AMRX) Investors - Sahm
Amneal Pharmaceuticals Inc Azioni (AMRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.28%
0.66%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):